Congress·In Committee·S. 1637

Sen. Mullin Pushes Bipartisan MVP Act to Only Pay for Medicaid Drugs if They Actually Work

MVP Act

10 months ago·View on Congress.gov

Part of: Bipartisan MVP Act Aims to Modernize Medicaid Access to Gene Therapies

⏸

Stalled

No legislative action in over 90 days.

↔Companion bill: Rep. Guthrie Introduces MVP Act to Link Medicaid Drug Payments to Patient Outcomes

Legislative Progress

Senate

House

President

Law

Key Points

This bill changes how Medicaid pays for very expensive medicines, like gene therapies. Instead of paying the full price upfront, the government would only pay the full amount if the medicine actually helps the patient get better.
Drug companies would be allowed to offer different price options to the government, as long as they offer the same deal to every state. This makes it easier for states to set up deals where they get a refund or pay less if a treatment doesn't work as promised.
The plan helps states afford miracle drugs that can have very high costs. It allows them to pay in installments over time, which helps keep state budgets stable while still getting patients the care they need.
It changes legal rules to make sure these performance-based refunds are allowed. This removes the risk of drug companies being accused of illegal kickbacks when they give money back to the government for a treatment that didn't help the patient.
A non-partisan government office will study the program by June 2029 to see if it helps patients get rare disease treatments and if it actually saves money for the states.

HealthcareEconomy Finance

Impact Analysis

Personal Impact

Who is affectedScoreImpactCertaintyScopeDurationSentiment

Scores: 1 = low, 5 = highSentiment: -5 to +5 (net benefit)

Milestones

2 milestones2 actions

May 7, 2025Senate

Read twice and referred to the Committee on Finance.

May 7, 2025

Introduced in Senate

What Happens Next

Projected impacts based on AI analysis

Within 6 months of enactment

HHS must issue rules on new drug pricing calculations and guidance for states on inpatient drug value-based deals

Within 180 days of enactment, new rules would clarify how drug prices are calculated under these arrangements and give states a roadmap for setting up outcome-based deals for hospital drugs

Related News

3 articles

Politico·about 1 month ago

Congress is About to Overhaul the Drug Market. Consumers May Never Feel It.

As Congress nears a major overhaul of prescription drug pricing, the bipartisan MVP Act remains a central pillar. The bill aims to modernize Medicaid by allowing states to pay for high-cost gene therapies based on patient outcomes, though critics worry the savings may not reach consumers.

CL~

AJMC·12 months ago

How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy

The Medicaid Value-Based Purchasing for Patients (MVP) Act is a top legislative priority for 2025. The bill seeks to codify 'multiple best price' rules, enabling Medicaid programs to enter into outcomes-based agreements for expensive cell and gene therapies without triggering price distortions.

Politico Pro·almost 3 years ago

Dems clash over drug price changes to Medicaid

House Democrats are divided over the MVP Act, which expands states' ability to pay for drugs based on patient outcomes. While supporters like Rep. Anna Eshoo argue it increases access to cures for sickle cell disease, others question if it aligns with broader drug pricing reform goals.

CL~

Related Bills

1 bill

H.R. 7871Identical bill

MVP Act

Mar 9 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Source Information

Document Type

Congressional Bill

Official Title

MVP Act

Bill NumberS 1637

Congress119th Congress

ChamberSenate

Latest ActionRead twice and referred to the Committee on Finance.

Sponsor

Cosponsors

(2)

D: 1R: 1

Data Sources

Congress.gov

Official legislative information

Analysis generated by AI. Always verify with official sources.